Critical reappraisal of remdesivir investigational trials in COVID-19

P. Brouqui (1, 2) , A. Giraud-Gatineau (3, 2) , D. Raoult (1, 2)

1 MEPHI - Microbes évolution phylogénie et infections
2 IHU Marseille - Institut Hospitalier Universitaire Méditerranée Infection
3 VITROME - Vecteurs - Infections tropicales et méditerranéennes

During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic. (C) 2020 The Author(s). Published by Elsevier Ltd.

Domains: Life Sciences [q-bio]

P. Brouqui, A. Giraud-Gatineau, D. Raoult. Critical reappraisal of remdesivir investigational trials in COVID-19. NEW MICROBES AND NEW INFECTIONS, 2020, 38, ⟨10.1016/j.nmni.2020.100745⟩. ⟨hal-03149257⟩